Michigan Prior Authorization Request Form For Prescription Drugs Instructions

Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available by the Department of Insurance and Financial Services to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left-hand corner.

- > This form is made available for use by prescribers to initiate a prior authorization request with the health insurer.
- ➤ Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- > "Prescriber" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL
- **>** 333.17708.
- ➤ "Prescription drug" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- ➤ Pursuant to MCL 500.2212c, prescribers and insurers must comply with required timeframes pertaining to the processing of a prior authorization request. Insurers may request additional information or clarification needed to process a prior authorization request.
- The prior authorization is considered granted if the insurer fails to grant the request, deny the request, or require additional information of the prescriber within 72 hours after the date and time of submission of an expedited prior authorization request or within 15 days after the date and time of submission of a standard prior authorization request. If additional information is requested by an insurer, a prior authorization request is considered to have been granted by the insurer if the insurer fails to grant the request, deny the request, or otherwise respond to the request of the prescriber within 72 hours after the date and time of submission of the additional information for an expedited prior authorization request; or within 15 days after the date and time of submission of the additional information for standard prior authorization request.
- ➤ The prior authorization is considered void if the prescriber fails to submit the additional information within 5 days after the date and time of the original submission of a properly completed expedited prior authorization request or within 21 days after the date and time of the original submission of a properly completed standard prior authorization request.
- ➤ In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient's ability to regain maximum function.

PRESCRIBERS, PLEASE SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN ONLY. Please do not send to the department.

Only provide the physician's direct contact number and initials if you are requesting an Expedited Review Request.

Michigan Prior Authorization Request Form for Prescription Drugs

Request Form for Prescription Drugs Fax: 800-424-7648

(PRESCRIBERS SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN)

	Standard Review Request	
	jeopardize the life or health of the patient or the patient's ability to re	gain maximum function.
Ph	nysician's Direct Contact Phone Number: I	nitials:
A)	Reason for Request	
,	\Box Initial Authorization Request \Box Renewal Request \Box DAW	
В)	Patient Demographics	
•	Is patient hospitalized: ☐ Yes ☐ No	
	Patient Name:	DOB:
	Patient Health Plan ID:	
	 Pharmacy Insurance Plan □ Priority □ Prime Therapeutics □ Blue Cross Blue Shi □ University of Michigan Prescription Drug Plan □ Total Health 	•
	☐ HealthPlus of Michigan ☐ Meridian Health Plan	
D)	Prescriber Information	
_,	Prescriber Name: NPI:	Specialty:
	DEA (required for controlled substance requests only):	
	Contact Name: Contact Phone:	
	Health Plan Provider ID (if accessible):	
E\	Pharmany Information (antional)	
•	Pharmacy Information (optional) Pharmacy Name: Pharmacy	Геlephone:
'	Tharmacy Name.	elephone.
F)	Requested Prescription Drug Information	
١	Drug Name: Streng	th:
	Dosing Schedule: Duration	on:
	Diagnosis (specific) with ICD#:	
	Place of infusion/injection (if applicable):	
	Facility Provider ID/NPI:	
	Has the patient already started the medication? \square Yes \square No	If so, when?

medical history, cเ	ırrent medica		also attach	nistory of present illness, past chart notes to support your
H) Failed/Contraind	icated Thera	pies		
Drug Name	Strength	Dosing Schedule	Duration	Adverse Event/Specific Failure
relevant diagnostic additional information insufficient clinical i	abs, measure on that may be nformation ma	e necessary for review y result in extended re	ment, etc.) Ple . Please note eview period c	formation is necessary such as ease refer to plan's website for that sending this form with or adverse determination. d is true, complete and fully formation with the intent to
Physician's Name:				
Physician's Signature				
PA 218 of 1956 as amend health plan requires prior	authorization fo		fits.	orm by prescribers when a patient's
Request Date:				
Approved:				
Approved By:		Denie	d By:	_
Effective Date:		Reaso	on for Denial:	
Additional Comments	:			



DIFS Is an equal opportunity employer/program.

Auxiliary aids, services and other reasonable accommodations are available upon request to individuals with disabilities.

Visit DIFS online at: www.michigan.gov/difs Phone DIFS toll-free at: 877-999-6442





Member's Last Name:							Member's First Name:																	

University of Michigan - Tavneos® (avacopan tablets)

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

Initial Requests					
Does the member have a diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, specifically, granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)?	Y	N			
Will the requested medication be used concurrently with either cyclophosphamide or rituximab?	Y	N			
Is the requested medication being prescribed by, or in consultation with, a nephrologist or rheumatologist?					
Renewal Requests					
Is the requested medication being prescribed by, or in consultation with, a nephrologist or rheumatologist?	Y	N			
Does the patient's physician or specialist provider attest that the patient continues to have a beneficial response to therapy?	Y	N			

Revised: 10/22/2022 | Effective: 02/07/2022